Q1 2026 · 13F-HR
SECTOR GAMMA ASholdings as filed
Filed 2026-05-07 · accession 0000945621-26-000644
$423.5M
Reported value
42
Positions
2026-03-31
Period end
The Brief · SECTOR GAMMA AS · Q1 2026
AI · grounded in 13F
SECTOR GAMMA AS closed its position in TMO for a reduction of $12.57M. The fund established new positions in UNH for $9.86M and ABT for $8.99M. Additionally, the fund increased its holdings in PFE by 26.97% and BMY by 10.99%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 110122108 | BMY | BRISTOL-MYERS SQUIBB CO | $50.2M | 11.9% | 827,901 | Common | SOLE |
| 58933Y105 | MRK | MERCK & CO INC | $31.3M | 7.39% | 260,340 | Common | SOLE |
| 717081103 | PFE | PFIZER INC | $30.6M | 7.24% | 1,091,385 | Common | SOLE |
| G5960L103 | MDT | MEDTRONIC PLC | $24.3M | 5.74% | 280,682 | Common | SOLE |
| 45337C102 | INCY | INCYTE CORP | $18.9M | 4.46% | 200,510 | Common | SOLE |
| 031162100 | AMGN | AMGEN INC | $16.6M | 3.92% | 47,155 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $16.5M | 3.90% | 90,096 | Common | SOLE |
| 98956P102 | ZBH | ZIMMER BIOMET HOLDINGS INC | $14.1M | 3.33% | 155,835 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $13.6M | 3.20% | 239,918 | Common | SOLE |
| 075887109 | BDX | BECTON DICKINSON & CO | $13.0M | 3.07% | 82,615 | Common | SOLE |
| 036752103 | ELV | ELEVANCE HEALTH INC FORMERLY | $12.9M | 3.04% | 43,962 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $12.7M | 3.00% | 169,468 | Common | SOLE |
| 14149Y108 | CAH | CARDINAL HEALTH INC | $11.6M | 2.74% | 54,897 | Common | SOLE |
| 91324P102 | UNH | UNITEDHEALTH GROUP INC | $9.9M | 2.33% | 36,435 | Common | SOLE |
| 126650100 | CVS | CVS HEALTH CORP | $9.7M | 2.30% | 135,337 | Common | SOLE |
| 116794108 | BRKR | BRUKER CORP | $9.2M | 2.17% | 254,010 | Common | SOLE |
| 36266G107 | GEHC | GE HEALTHCARE TECHNOLOGIES I | $9.0M | 2.12% | 126,418 | Common | SOLE |
| 002824100 | ABT | ABBOTT LABS | $9.0M | 2.12% | 87,532 | Common | SOLE |
| 375558103 | GILD | GILEAD SCIENCES INC | $7.4M | 1.75% | 53,247 | Common | SOLE |
| 516544103 | LNTH | LANTHEUS HLDGS INC | $7.1M | 1.67% | 93,344 | Common | SOLE |
| 46266C105 | IQV | IQVIA HLDGS INC | $6.9M | 1.62% | 40,230 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $6.7M | 1.58% | 286,007 | Common | SOLE |
| 090572207 | BIO | BIO RAD LABS INC | $6.6M | 1.56% | 23,750 | Common | SOLE |
| N72482156 | QGEN | QIAGEN NV | $6.5M | 1.54% | 162,371 | Common | SOLE |
| 05352A100 | AVTR | AVANTOR INC | $5.5M | 1.29% | 695,403 | Common | SOLE |
| 15135B101 | CNC | CENTENE CORP DEL | $5.3M | 1.26% | 162,405 | Common | SOLE |
| 875372203 | TNDM | TANDEM DIABETES CARE INC | $5.1M | 1.21% | 267,091 | Common | SOLE |
| 69366J200 | PTCT | PTC THERAPEUTICS INC | $5.1M | 1.21% | 75,000 | Common | SOLE |
| 504922105 | LH | LABCORP HOLDINGS INC | $5.1M | 1.20% | 19,019 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $4.9M | 1.15% | 21,305 | Common | SOLE |
| 28176E108 | EW | EDWARDS LIFESCIENCES CORP | $4.8M | 1.14% | 60,402 | Common | SOLE |
| 252131107 | DXCM | DEXCOM INC | $3.5M | 0.83% | 56,122 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $3.4M | 0.81% | 94,195 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $3.3M | 0.79% | 411,810 | Common | SOLE |
| 444859102 | HUM | HUMANA INC | $3.3M | 0.79% | 19,202 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $3.3M | 0.78% | 44,263 | Common | SOLE |
| 462260100 | IOVA | IOVANCE BIOTHERAPEUTICS INC | $3.2M | 0.75% | 900,000 | Common | SOLE |
| 24823R105 | DNLI | DENALI THERAPEUTICS INC | $3.1M | 0.74% | 162,710 | Common | SOLE |
| 039697107 | ARDX | ARDELYX INC | $3.1M | 0.73% | 516,131 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $3.1M | 0.73% | 80,000 | Common | SOLE |
| 68622V106 | OGN | ORGANON & CO | $2.3M | 0.53% | 375,974 | Common | SOLE |
| 04280A100 | ARWR | ARROWHEAD PHARMACEUTICALS IN | $1.9M | 0.44% | 30,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.